Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Omnicell, Inc. or Veradigm Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Omnicell, Inc. and Veradigm Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Omnicell, Inc. and Veradigm Inc.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; clinical data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. Additionally, the company serves physician practices, hospitals, laboratory and radiology centers, urgent care facilities, health IT companies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Latest Health Care Equipment & Supplies and Omnicell, Inc., Veradigm Inc. Stock News

As of September 2, 2026, Omnicell, Inc. had a $1.6 billion market capitalization, compared to the Health Care Equipment & Supplies median of $416.1 million. Omnicell, Inc.’s stock is down 23.6% in 2026, up 3.5% in the previous five trading days and up 8.13% in the past year.

Currently, Omnicell, Inc.’s price-earnings ratio is 41.3. Omnicell, Inc.’s trailing 12-month revenue is $1.2 billion with a 3.1% net profit margin. Year-over-year quarterly sales growth most recently was 7.4%. Analysts expect adjusted earnings to reach $2.269 per share for the current fiscal year. Omnicell, Inc. does not currently pay a dividend.

As of September 2, 2026, Veradigm Inc. had a $512.3 million market cap, putting it in the 37th percentile of all stocks. Veradigm Inc.’s stock is down 2.1% in 2026, down 2.3% in the previous five trading days and NA 0% in the past year.

Currently, Veradigm Inc. does not have a price-earnings ratio. Veradigm Inc.’s trailing 12-month revenue is $594.4 million with a -49.0% net profit margin. Year-over-year quarterly sales growth most recently was 5.0%. There are no analysts providing consensus earnings estimates for the current fiscal year. Veradigm Inc. does not currently pay a dividend.

How We Compare Omnicell, Inc. and Veradigm Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Omnicell, Inc. and Veradigm Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Omnicell, Inc. and Veradigm Inc. Stock Value Grades

Company	Ticker	Value
Omnicell, Inc.	OMCL	C
Veradigm Inc.	MDRX	A

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Omnicell, Inc. has a Value Score of 54, which is Average. Veradigm Inc. has a Value Score of 99, which is Deep Value.

The Value Stock Winner: Veradigm Inc.

As you can clearly see from the Value Grade breakdown above, Veradigm Inc. is considered to have better value than Omnicell, Inc.. For investors who focus solely on a company’s valuation, Veradigm Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Omnicell, Inc. and Veradigm Inc. Growth Grades

Company	Ticker	Growth
Omnicell, Inc.	OMCL	B
Veradigm Inc.	MDRX	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Omnicell, Inc. has a Growth Score of 77, which is Strong. Veradigm Inc. has a Growth Score of 10, which is Very Weak.

The Growth Grade Winner: Omnicell, Inc.

As you can clearly see from the Growth Grade breakdown above, Omnicell, Inc. has a more attractive growth grade than Veradigm Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Omnicell, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Omnicell, Inc. and Veradigm Inc.’s Momentum Grades

Company	Ticker	Momentum
Omnicell, Inc.	OMCL	D
Veradigm Inc.	MDRX	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Omnicell, Inc. has a Momentum Score of 32, which is Weak. Veradigm Inc. has a Momentum Score of 36, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither Omnicell, Inc. or Veradigm Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Omnicell, Inc. or Veradigm Inc. is the better investment when it comes to momentum.

Other Omnicell, Inc. and Veradigm Inc. Grades

In addition to Momentum, Growth and Value, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Omnicell, Inc. and Veradigm Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Omnicell, Inc. or Veradigm Inc. Stock?

Overall, Omnicell, Inc. stock has a Value Score of 54, Growth Score of 77 and Momentum Score of 32.

Veradigm Inc. stock has a Value Score of 99, Growth Score of 10 and Momentum Score of 36.

Comparing Omnicell, Inc. and Veradigm Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.